(Q37766888)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20569080%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

review article

1 reference

title

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20569080%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20569080%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Sébastien Albert

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20569080%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Maria Serova

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20569080%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Chantal Dreyer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20569080%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Marie-Paule Sablin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20569080%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Eric Raymond

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20569080%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

English

0 references

publication date

1 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20569080%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

6 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20569080%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20569080%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

919-930

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20569080%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20569080%20AND%20SRC:MED&resulttype=core&format=json

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

6 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

The role of mTOR in the management of solid tumors: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

The tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Regulation of TORC1 by Rag GTPases in nutrient response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Dysregulation of the TSC-mTOR pathway in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

The TSC1-TSC2 complex is required for proper activation of mTOR complex 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Perifosine: update on a novel Akt inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.499121